{
    "clinical_study": {
        "@rank": "159786", 
        "arm_group": {
            "arm_group_label": "cabazitaxel and lapatinib combination", 
            "arm_group_type": "Experimental", 
            "description": "Cabazitaxel  1-hour IV infusion on Day 1 of each 3 week cycle (dose to be determined)\nLapatinib PO once daily (dose to be determined)\nTreatment cycles will be repeated every 3 weeks."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial will combine two agents, cabazitaxel and lapatinib, to treat patients\n      with metastatic breast cancer (MBC) which has metastasized to the brain.  The first portion\n      of the study will determine the optimal dose of the cabazitaxel/lapatinib combination to\n      administer to patients.  After determining the optimal dose, patients will continue\n      treatment with cabazitaxel and lapatinib to assess response to treatment with these agents."
        }, 
        "brief_title": "Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer With Intracranial Metastases", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasm Metastasis", 
                "Neoplasms, Second Primary"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, non-randomized, Phase II study with a lead-in safety cohort.\n      Through the safety lead-in portion of this trial we will define the optimal dose of\n      cabazitaxel when given in combination with lapatinib for patients with HER2-positive MBC and\n      CNS metastases.  The Phase II portion will further assess intracranial response rate in\n      patients with HER2-positive MBC and CNS metastases.  Toxicity and progression free survival\n      (PFS)  will be obtained and evaluated.  The trial will be conducted at multiple study sites\n      by SCRI Development Innovations."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patients with HER2-positive MBC and unequivocal evidence of brain metastases.\n\n          2. Documented HER2-positive tumor status at study entry defined as:\n\n               -  Immunohistochemical (IHC) score 3+ or\n\n               -  IHC score 1-2+ and confirmed as FISH (Fluorescence in situ  hybridization)\n                  positive (defined by ratio >2.2) or\n\n               -  FISH or SISH (Silver in situ hybridization) positive (ratio >2.2)\n\n          3. Patient must have at least one measurable brain lesion (defined as any lesion \u2265 1.0\n             cm in the longest dimension), on T1 weighted, gadolinium enhanced MRI.  Patients may\n             have had surgical excisions of brain metastases provided at least one lesions meets\n             the following criteria:\n\n               -  Patients with brain metastases previously untreated with any intra-cranial\n                  radiation (i.e. no WBRT or SRS) must have at least one intra-cranial tumor\n                  lesion that is = 1.0 cm.\n\n               -  Patients with brain metastases previously treated with WBRT only must have at\n                  least one intra-cranial tumor lesion \u22651.0 cm and must have evidence of\n                  intra-cranial progressive disease.\n\n               -  Patients previously treated with WBRT and SRS must have at least one\n                  intracranial tumor lesion \u22651.0 cm that was not treated with SRS and must have\n                  evidence of intra-cranial progressive disease\n\n               -  Patients previously treated with SRS must either demonstrate disease progression\n                  \u226512 weeks after completing stereotactic radiosurgery (SRS) with a lesion\n                  measuring \u2265 1.0 cm or must have at least one intra-cranial tumor lesion \u22651.0 cm\n                  that was not treated with SRS.\n\n          4. Patients who have received WBRT for intra-cranial metastases are eligible if\n             treatment was completed \u226528 days prior to the first dose of study drug.\n\n          5. Estrogen receptor (ER) and progesterone receptor (PR) status in the primary or most\n             recent tumor assessment must be known or pending at the time of study registration.\n             Patient's ER/PR status (i.e., positive or negative) does not influence enrollment but\n             is a requirement.\n\n          6. Patient must have received prior treatment with HER2-directed therapy such as\n             trastuzumab, either in the adjuvant or metastatic setting.\n\n          7. Patients without prior chemotherapy for MBC are eligible provided the patients\n             relapsed during adjuvant therapy with trastuzumab or \u22646 months following completion\n             of adjuvant therapy.  Otherwise, there is no specific minimum or maximum number of\n             previous chemotherapy regimens for MBC.\n\n          8. Patients must have completed cytotoxic chemotherapy \u226521 days (for an every 3-week\n             regimen) or \u226514 days (for an every 2-week or weekly regimen) and   have  recovered\n             from or come to a new chronic or stable baseline from all treatment-related\n             toxicities in order to be eligible for study treatment.\n\n               -  Patient must have completed biologic therapy \u22653 weeks or 5-half lives whichever\n                  is shorter.\n\n               -  Patient must be discontinued from hormonal therapy a minimum of 1 day prior to\n                  the first dose of study treatment.\n\n               -  Patients receiving palliative radiation to bone, soft tissue or any other\n                  disease sites must have completed this \u22651 week prior to the first dose of study\n                  treatment.\n\n          9. Patients must have recovered (>2 week recovery is mandated) from any   acute\n             neurosurgical intervention for metastatic CNS disease (e.g., resection, shunt\n             placement) and must be clinically stable.  These patients must have residual\n             measurable CNS lesion(s) following the surgical procedure if this site is to serve as\n             the target lesion.\n\n         10. Patients must be neurologically stable, defined as being on stable low doses of\n             corticosteroids (\u226420 mg/day prednisone or its equivalent) and anticonvulsants\n             (excluding enzyme-inducing anti-epileptic drugs [phenytoin, phenobarbitol,\n             carbamazepine, fosphenytoin, primidone, oxcarbazepine]) for \u22655 days prior to\n             obtaining baseline gadolinium enhanced MRI (Gd-MRI) of the brain and \u22655 days prior to\n             the first dose of study treatment.\n\n         11. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to 2.\n\n         12. Adequate hematologic, renal, and hepatic function.\n\n         13. Adequate coagulation parameters.\n\n         14. Other laboratory testing:\n\n               -  Serum magnesium \u2265 the institutional lower limit of normal (LLN)\n\n               -  Serum potassium \u2265 the institutional LLN\n\n         15. Male patients willing to use adequate contraceptive measures.\n\n         16. Female patients who are not of child-bearing potential, and female patients of\n             child-bearing potential who agree to use adequate contraceptive measures, who are not\n             breastfeeding, and who have a negative serum or urine pregnancy test within 72 hours\n             prior to start of treatment.\n\n         17. Male or female patients.\n\n         18. Life expectancy \u226512 weeks.\n\n         19. Age \u226518 years of age.\n\n         20. Ability to swallow oral medications.\n\n         21. Willingness and ability to comply with trial and follow-up procedures.\n\n         22. Ability to understand the nature of this trial and give written informed consent.\n\n        Exclusion Criteria:\n\n          1. Previous treatment with lapatinib for MBC (adjuvant/neoadjuvant lapatinib permitted).\n\n          2. Previous treatment with cabazitaxel.\n\n          3. CNS disease requiring immediate neurosurgical intervention (e.g., resection, shunt\n             placement, etc.).\n\n          4. Leptomeningeal metastases as the only site of CNS metastases.  Patients with\n             parenchymal brain metastases and leptomeningeal metastases are eligible provided they\n             meet all other eligibility criteria.\n\n          5. Peripheral neuropathy \u2265Grade 2 (CTCAE v4.0).\n\n          6. Concurrent treatment with radiation therapy, hormonal therapy, biologic therapy or\n             chemotherapy is not allowed.  Low dose corticosteroids (\u226430 mg/day prednisone or its\n             equivalent) are allowed.\n\n          7. Concurrent treatment with drugs known to be moderate and strong inhibitors or\n             inducers of isoenzyme CYP3A that cannot be discontinued or switched to different\n             medication prior to starting study drug.\n\n          8. Concurrent use of St. John's wort and grapefruit/grapefruit juice \u22647 days prior to\n             starting study drug is not allowed.\n\n          9. Presence of active gastrointestinal (GI) disease or other condition that in the\n             opinion of the investigator will interfere significantly with the absorption,\n             distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease,\n             uncontrolled nausea, or vomiting).\n\n         10. Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis\n             C (HCV).\n\n         11. Presence of other active cancers, or history of treatment for invasive cancer \u22653\n             years.  Patients with stage I cancer who have received definitive local treatment\n             with curative intent at least 3 years previously, and are considered unlikely to\n             recur are eligible.  All patients with previously treated in situ carcinoma (i.e.\n             non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.\n\n         12. Any severe and/or uncontrolled medical conditions or other conditions that could\n             affect participation in the study such as:\n\n               -  Symptomatic congestive heart failure (CHF) of New York Heart Association Class\n                  III or IV.\n\n               -  QTc > 480 ms on screening ECG (using the Fredericia formula)\n\n               -  Poorly controlled or clinically significant atherosclerotic vascular disease\n                  including cerebrovascular accident (CVA), transient ischemic attack (TIA),\n                  angioplasty, cardiac or vascular stenting in the past 6 months\n\n               -  Active (acute or chronic) or uncontrolled severe infections.\n\n               -  Active hepatic or biliary disease (except for patients with Gilbert's syndrome,\n                  asymptomatic gallstones, liver metastases, or stable chronic liver disease per\n                  investigator assessment).\n\n         13. Known hypersensitivity to cabazitaxel or other drugs formulated with polysorbate 80.\n\n         14. Psychological, familial, sociological, or geographical conditions that do not permit\n             compliance with the protocol.\n\n         15. Inability or unwillingness to comply with study and/or follow-up procedures outlined\n             in the protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934894", 
            "org_study_id": "SCRI BRE 200"
        }, 
        "intervention": [
            {
                "arm_group_label": "cabazitaxel and lapatinib combination", 
                "intervention_name": "cabazitaxel", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Jevtana", 
                    "XRP6258"
                ]
            }, 
            {
                "arm_group_label": "cabazitaxel and lapatinib combination", 
                "intervention_name": "lapatinib", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Tykerb", 
                    "GW572016"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Lapatinib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "HER2-positive breast cancer", 
            "intracranial metastases", 
            "lapatinib", 
            "cabazitaxel"
        ], 
        "lastchanged_date": "April 9, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fort Myers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33916"
                    }, 
                    "name": "Florida Cancer Specialists - South"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Petersburg", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33705"
                    }, 
                    "name": "Florida Cancer Specialists-North"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45242"
                    }, 
                    "name": "Oncology Hematology Care Inc."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "asksarah@scresearch.net", 
                    "last_name": "Central Contact", 
                    "phone": "877-691-7274"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Tennessee Oncology"
                }, 
                "investigator": {
                    "last_name": "Denise A. Yardley, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study With Lead-in Safety Cohort of Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases", 
        "overall_contact": {
            "email": "asksarah@scresearch.net", 
            "last_name": "Denise A. Yardley, MD", 
            "phone": "877-691-7274"
        }, 
        "overall_contact_backup": {
            "email": "asksarah@scresearch.net", 
            "last_name": "Trials Info", 
            "phone": "877-691-7274"
        }, 
        "overall_official": {
            "affiliation": "SCRI Development Innovations", 
            "last_name": "Denise A. Yardley, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Determine the CNS response rate of the combination of cabazitaxel and lapatinib when administered as treatment for CNS metastases in HER2-positive MBC patients.", 
                "measure": "Central Nervous System (CNS) response rate", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Evaluate the safety of cabazitaxel and lapatinib when administered as treatment for CNS metastases in HER2-positive MBC patients.", 
                "measure": "Number of patients with grade 3/4 adverse events as a measure of safety.", 
                "safety_issue": "Yes", 
                "time_frame": "24 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934894"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Evaluate the clinical benefit rate of the combination in the treatment of CNS metastases (CR+PR +SD >= 6 months).", 
                "measure": "Clinical benefit rate (CNS metastases)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Evaluate the 3- and 6- month CNS progression free survival rate.", 
                "measure": "CNS progression free survival rate", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Evaluate the extra-cranial response rate of the combination (CR+PR+SD >= 6 months).", 
                "measure": "Extra-cranial response rate", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }, 
            {
                "description": "Evaluate the clinical benefit rate of the combination for extracranial disease (CR+PR+SD >= 6 months)", 
                "measure": "Clinical benefit rate (extracranial disease)", 
                "safety_issue": "No", 
                "time_frame": "24 months"
            }
        ], 
        "source": "SCRI Development Innovations, LLC", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "GlaxoSmithKline", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Sanofi", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "SCRI Development Innovations, LLC", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}